Physician profile
Sara A Fish
NPI 1043982945
$2,449.97
in general payments reported to CMS, 2019-2025
12 companies · $108 in 2025
The $108 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $36.00 · 2022: $290 · 2023: $1,653 · 2024: $363 · 2025: $108.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,256 · Travel and Lodging: $868.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,256.01 |
| Travel and Lodging | $867.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,622.22 | 2021-2025 | Micra, Reveal Linq, Onyx Frontier |
| Janssen Pharmaceuticals, INC | $241.95 | 2022-2023 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $188.51 | 2022-2025 | Lifevest |
| Pfizer INC. | $88.29 | 2022-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $77.25 | 2022-2024 | Jardiance |
| Boston Scientific Corporation | $67.22 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $46.27 | 2023 | Farxiga, Brilinta |
| E.R. Squibb & Sons, L.L.C. | $29.40 | 2025 | Camzyos |
| Abiomed | $27.17 | 2024 | Impella |
| Philips North America LLC | $23.27 | 2024 | (Am5) Lead Management |
| Sanofi-Aventis U.S. LLC | $20.65 | 2024 | |
| Novo Nordisk INC | $17.77 | 2025 | Wegovy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Fish listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.